nodes	percent_of_prediction	percent_of_DWPC	metapath
Telmisartan—PPARG—urinary bladder cancer	0.414	1	CbGaD
Telmisartan—ABCB1—Mitomycin—urinary bladder cancer	0.0453	0.112	CbGbCtD
Telmisartan—SLCO1B3—Methotrexate—urinary bladder cancer	0.0369	0.091	CbGbCtD
Telmisartan—ABCC2—Carboplatin—urinary bladder cancer	0.034	0.084	CbGbCtD
Telmisartan—ABCG2—Fluorouracil—urinary bladder cancer	0.0309	0.0764	CbGbCtD
Telmisartan—ABCG2—Carboplatin—urinary bladder cancer	0.0308	0.0759	CbGbCtD
Telmisartan—ABCC2—Cisplatin—urinary bladder cancer	0.0291	0.0718	CbGbCtD
Telmisartan—ABCC2—Etoposide—urinary bladder cancer	0.0286	0.0705	CbGbCtD
Telmisartan—ABCG2—Cisplatin—urinary bladder cancer	0.0263	0.0649	CbGbCtD
Telmisartan—ABCG2—Etoposide—urinary bladder cancer	0.0258	0.0638	CbGbCtD
Telmisartan—ABCC2—Doxorubicin—urinary bladder cancer	0.0195	0.0481	CbGbCtD
Telmisartan—ABCC2—Methotrexate—urinary bladder cancer	0.0189	0.0466	CbGbCtD
Telmisartan—ABCG2—Doxorubicin—urinary bladder cancer	0.0176	0.0435	CbGbCtD
Telmisartan—ABCG2—Methotrexate—urinary bladder cancer	0.0171	0.0421	CbGbCtD
Telmisartan—ABCB1—Gemcitabine—urinary bladder cancer	0.013	0.0322	CbGbCtD
Telmisartan—ABCB1—Cisplatin—urinary bladder cancer	0.00948	0.0234	CbGbCtD
Telmisartan—ABCB1—Etoposide—urinary bladder cancer	0.00931	0.023	CbGbCtD
Telmisartan—ABCB1—Doxorubicin—urinary bladder cancer	0.00635	0.0157	CbGbCtD
Telmisartan—ABCB1—Methotrexate—urinary bladder cancer	0.00615	0.0152	CbGbCtD
Telmisartan—CYP2C19—urine—urinary bladder cancer	0.00289	0.105	CbGeAlD
Telmisartan—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.00188	1	CbGdCrCtD
Telmisartan—AGTR1—prostate gland—urinary bladder cancer	0.00167	0.0605	CbGeAlD
Telmisartan—Losartan—UGT2B7—urinary bladder cancer	0.00157	1	CrCbGaD
Telmisartan—PPARG—prostate gland—urinary bladder cancer	0.00137	0.0497	CbGeAlD
Telmisartan—SLCO1B3—vagina—urinary bladder cancer	0.00136	0.0492	CbGeAlD
Telmisartan—AGTR1—epithelium—urinary bladder cancer	0.00123	0.0444	CbGeAlD
Telmisartan—ABCC2—prostate gland—urinary bladder cancer	0.00121	0.0437	CbGeAlD
Telmisartan—AGTR1—smooth muscle tissue—urinary bladder cancer	0.00118	0.0428	CbGeAlD
Telmisartan—AGTR1—renal system—urinary bladder cancer	0.00114	0.0412	CbGeAlD
Telmisartan—PPARG—epithelium—urinary bladder cancer	0.00101	0.0365	CbGeAlD
Telmisartan—PPARG—smooth muscle tissue—urinary bladder cancer	0.000971	0.0352	CbGeAlD
Telmisartan—PPARG—renal system—urinary bladder cancer	0.000935	0.0339	CbGeAlD
Telmisartan—PPARG—urethra—urinary bladder cancer	0.000918	0.0333	CbGeAlD
Telmisartan—AGTR1—female reproductive system—urinary bladder cancer	0.00091	0.033	CbGeAlD
Telmisartan—ABCG2—prostate gland—urinary bladder cancer	0.000879	0.0319	CbGeAlD
Telmisartan—AGTR1—vagina—urinary bladder cancer	0.000823	0.0298	CbGeAlD
Telmisartan—ABCC2—renal system—urinary bladder cancer	0.000822	0.0298	CbGeAlD
Telmisartan—PPARG—female reproductive system—urinary bladder cancer	0.000749	0.0271	CbGeAlD
Telmisartan—ABCG2—seminal vesicle—urinary bladder cancer	0.000744	0.027	CbGeAlD
Telmisartan—PPARG—vagina—urinary bladder cancer	0.000677	0.0245	CbGeAlD
Telmisartan—ABCC2—female reproductive system—urinary bladder cancer	0.000658	0.0239	CbGeAlD
Telmisartan—ABCG2—urethra—urinary bladder cancer	0.000589	0.0213	CbGeAlD
Telmisartan—AGTR1—lymph node—urinary bladder cancer	0.000532	0.0193	CbGeAlD
Telmisartan—CYP2C19—vagina—urinary bladder cancer	0.000511	0.0185	CbGeAlD
Telmisartan—PPARG—lymph node—urinary bladder cancer	0.000438	0.0159	CbGeAlD
Telmisartan—ABCG2—vagina—urinary bladder cancer	0.000434	0.0157	CbGeAlD
Telmisartan—ABCB1—prostate gland—urinary bladder cancer	0.000433	0.0157	CbGeAlD
Telmisartan—ABCC2—lymph node—urinary bladder cancer	0.000385	0.014	CbGeAlD
Telmisartan—ABCB1—seminal vesicle—urinary bladder cancer	0.000367	0.0133	CbGeAlD
Telmisartan—ABCB1—epithelium—urinary bladder cancer	0.000319	0.0115	CbGeAlD
Telmisartan—ABCB1—renal system—urinary bladder cancer	0.000295	0.0107	CbGeAlD
Telmisartan—ABCB1—urethra—urinary bladder cancer	0.00029	0.0105	CbGeAlD
Telmisartan—ABCG2—lymph node—urinary bladder cancer	0.000281	0.0102	CbGeAlD
Telmisartan—ABCB1—female reproductive system—urinary bladder cancer	0.000237	0.00858	CbGeAlD
Telmisartan—ABCB1—vagina—urinary bladder cancer	0.000214	0.00776	CbGeAlD
Telmisartan—ABCB1—lymph node—urinary bladder cancer	0.000138	0.00502	CbGeAlD
Telmisartan—Rhinitis—Epirubicin—urinary bladder cancer	8.08e-05	0.000687	CcSEcCtD
Telmisartan—Abdominal pain—Etoposide—urinary bladder cancer	8.07e-05	0.000687	CcSEcCtD
Telmisartan—Body temperature increased—Etoposide—urinary bladder cancer	8.07e-05	0.000687	CcSEcCtD
Telmisartan—Conjunctivitis—Doxorubicin—urinary bladder cancer	8.07e-05	0.000687	CcSEcCtD
Telmisartan—Urinary tract infection—Doxorubicin—urinary bladder cancer	8.07e-05	0.000687	CcSEcCtD
Telmisartan—Eye disorder—Methotrexate—urinary bladder cancer	8.05e-05	0.000685	CcSEcCtD
Telmisartan—Diarrhoea—Fluorouracil—urinary bladder cancer	8.05e-05	0.000685	CcSEcCtD
Telmisartan—Tinnitus—Methotrexate—urinary bladder cancer	8.03e-05	0.000683	CcSEcCtD
Telmisartan—Hypoaesthesia—Epirubicin—urinary bladder cancer	8.02e-05	0.000682	CcSEcCtD
Telmisartan—Asthenia—Cisplatin—urinary bladder cancer	8e-05	0.000681	CcSEcCtD
Telmisartan—Pharyngitis—Epirubicin—urinary bladder cancer	8e-05	0.00068	CcSEcCtD
Telmisartan—Cardiac disorder—Methotrexate—urinary bladder cancer	7.99e-05	0.00068	CcSEcCtD
Telmisartan—Urinary tract disorder—Epirubicin—urinary bladder cancer	7.96e-05	0.000677	CcSEcCtD
Telmisartan—Oedema peripheral—Epirubicin—urinary bladder cancer	7.94e-05	0.000675	CcSEcCtD
Telmisartan—Haematuria—Doxorubicin—urinary bladder cancer	7.92e-05	0.000674	CcSEcCtD
Telmisartan—Connective tissue disorder—Epirubicin—urinary bladder cancer	7.92e-05	0.000674	CcSEcCtD
Telmisartan—Urethral disorder—Epirubicin—urinary bladder cancer	7.9e-05	0.000672	CcSEcCtD
Telmisartan—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	7.86e-05	0.000668	CcSEcCtD
Telmisartan—Epistaxis—Doxorubicin—urinary bladder cancer	7.83e-05	0.000667	CcSEcCtD
Telmisartan—Angiopathy—Methotrexate—urinary bladder cancer	7.81e-05	0.000665	CcSEcCtD
Telmisartan—Sinusitis—Doxorubicin—urinary bladder cancer	7.79e-05	0.000663	CcSEcCtD
Telmisartan—Immune system disorder—Methotrexate—urinary bladder cancer	7.78e-05	0.000662	CcSEcCtD
Telmisartan—Dizziness—Fluorouracil—urinary bladder cancer	7.78e-05	0.000662	CcSEcCtD
Telmisartan—Visual impairment—Epirubicin—urinary bladder cancer	7.77e-05	0.000661	CcSEcCtD
Telmisartan—Mediastinal disorder—Methotrexate—urinary bladder cancer	7.76e-05	0.00066	CcSEcCtD
Telmisartan—Chills—Methotrexate—urinary bladder cancer	7.73e-05	0.000657	CcSEcCtD
Telmisartan—Diarrhoea—Cisplatin—urinary bladder cancer	7.63e-05	0.000649	CcSEcCtD
Telmisartan—Vomiting—Gemcitabine—urinary bladder cancer	7.6e-05	0.000647	CcSEcCtD
Telmisartan—Bradycardia—Doxorubicin—urinary bladder cancer	7.59e-05	0.000646	CcSEcCtD
Telmisartan—Mental disorder—Methotrexate—urinary bladder cancer	7.54e-05	0.000642	CcSEcCtD
Telmisartan—Rash—Gemcitabine—urinary bladder cancer	7.54e-05	0.000642	CcSEcCtD
Telmisartan—Dermatitis—Gemcitabine—urinary bladder cancer	7.53e-05	0.000641	CcSEcCtD
Telmisartan—Eye disorder—Epirubicin—urinary bladder cancer	7.53e-05	0.000641	CcSEcCtD
Telmisartan—Hypersensitivity—Etoposide—urinary bladder cancer	7.52e-05	0.00064	CcSEcCtD
Telmisartan—Tinnitus—Epirubicin—urinary bladder cancer	7.51e-05	0.000639	CcSEcCtD
Telmisartan—Erythema—Methotrexate—urinary bladder cancer	7.5e-05	0.000638	CcSEcCtD
Telmisartan—Malnutrition—Methotrexate—urinary bladder cancer	7.5e-05	0.000638	CcSEcCtD
Telmisartan—Headache—Gemcitabine—urinary bladder cancer	7.49e-05	0.000638	CcSEcCtD
Telmisartan—Flushing—Epirubicin—urinary bladder cancer	7.48e-05	0.000636	CcSEcCtD
Telmisartan—Cardiac disorder—Epirubicin—urinary bladder cancer	7.48e-05	0.000636	CcSEcCtD
Telmisartan—Vomiting—Fluorouracil—urinary bladder cancer	7.48e-05	0.000636	CcSEcCtD
Telmisartan—Rhinitis—Doxorubicin—urinary bladder cancer	7.48e-05	0.000636	CcSEcCtD
Telmisartan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	7.42e-05	0.000631	CcSEcCtD
Telmisartan—Rash—Fluorouracil—urinary bladder cancer	7.41e-05	0.000631	CcSEcCtD
Telmisartan—Dermatitis—Fluorouracil—urinary bladder cancer	7.41e-05	0.00063	CcSEcCtD
Telmisartan—Pharyngitis—Doxorubicin—urinary bladder cancer	7.4e-05	0.00063	CcSEcCtD
Telmisartan—Headache—Fluorouracil—urinary bladder cancer	7.37e-05	0.000627	CcSEcCtD
Telmisartan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	7.36e-05	0.000627	CcSEcCtD
Telmisartan—Oedema peripheral—Doxorubicin—urinary bladder cancer	7.35e-05	0.000625	CcSEcCtD
Telmisartan—Dysgeusia—Methotrexate—urinary bladder cancer	7.34e-05	0.000625	CcSEcCtD
Telmisartan—Asthenia—Etoposide—urinary bladder cancer	7.33e-05	0.000623	CcSEcCtD
Telmisartan—Connective tissue disorder—Doxorubicin—urinary bladder cancer	7.33e-05	0.000623	CcSEcCtD
Telmisartan—Angiopathy—Epirubicin—urinary bladder cancer	7.31e-05	0.000622	CcSEcCtD
Telmisartan—Urethral disorder—Doxorubicin—urinary bladder cancer	7.31e-05	0.000622	CcSEcCtD
Telmisartan—Immune system disorder—Epirubicin—urinary bladder cancer	7.28e-05	0.000619	CcSEcCtD
Telmisartan—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.26e-05	0.000618	CcSEcCtD
Telmisartan—Back pain—Methotrexate—urinary bladder cancer	7.25e-05	0.000617	CcSEcCtD
Telmisartan—Chills—Epirubicin—urinary bladder cancer	7.23e-05	0.000615	CcSEcCtD
Telmisartan—Pruritus—Etoposide—urinary bladder cancer	7.23e-05	0.000615	CcSEcCtD
Telmisartan—Arrhythmia—Epirubicin—urinary bladder cancer	7.2e-05	0.000612	CcSEcCtD
Telmisartan—Visual impairment—Doxorubicin—urinary bladder cancer	7.19e-05	0.000611	CcSEcCtD
Telmisartan—Nausea—Gemcitabine—urinary bladder cancer	7.1e-05	0.000604	CcSEcCtD
Telmisartan—Vomiting—Cisplatin—urinary bladder cancer	7.09e-05	0.000603	CcSEcCtD
Telmisartan—Mental disorder—Epirubicin—urinary bladder cancer	7.06e-05	0.000601	CcSEcCtD
Telmisartan—Rash—Cisplatin—urinary bladder cancer	7.03e-05	0.000598	CcSEcCtD
Telmisartan—Dermatitis—Cisplatin—urinary bladder cancer	7.02e-05	0.000598	CcSEcCtD
Telmisartan—Erythema—Epirubicin—urinary bladder cancer	7.01e-05	0.000597	CcSEcCtD
Telmisartan—Malnutrition—Epirubicin—urinary bladder cancer	7.01e-05	0.000597	CcSEcCtD
Telmisartan—Diarrhoea—Etoposide—urinary bladder cancer	6.99e-05	0.000595	CcSEcCtD
Telmisartan—Nausea—Fluorouracil—urinary bladder cancer	6.99e-05	0.000594	CcSEcCtD
Telmisartan—Eye disorder—Doxorubicin—urinary bladder cancer	6.97e-05	0.000593	CcSEcCtD
Telmisartan—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.95e-05	0.000592	CcSEcCtD
Telmisartan—Tinnitus—Doxorubicin—urinary bladder cancer	6.95e-05	0.000591	CcSEcCtD
Telmisartan—Anaemia—Methotrexate—urinary bladder cancer	6.93e-05	0.000589	CcSEcCtD
Telmisartan—Flushing—Doxorubicin—urinary bladder cancer	6.92e-05	0.000589	CcSEcCtD
Telmisartan—Cardiac disorder—Doxorubicin—urinary bladder cancer	6.92e-05	0.000589	CcSEcCtD
Telmisartan—Flatulence—Epirubicin—urinary bladder cancer	6.91e-05	0.000588	CcSEcCtD
Telmisartan—Tension—Epirubicin—urinary bladder cancer	6.88e-05	0.000586	CcSEcCtD
Telmisartan—Dysgeusia—Epirubicin—urinary bladder cancer	6.87e-05	0.000584	CcSEcCtD
Telmisartan—Nervousness—Epirubicin—urinary bladder cancer	6.81e-05	0.00058	CcSEcCtD
Telmisartan—Back pain—Epirubicin—urinary bladder cancer	6.79e-05	0.000577	CcSEcCtD
Telmisartan—Angiopathy—Doxorubicin—urinary bladder cancer	6.76e-05	0.000576	CcSEcCtD
Telmisartan—Malaise—Methotrexate—urinary bladder cancer	6.76e-05	0.000575	CcSEcCtD
Telmisartan—Dizziness—Etoposide—urinary bladder cancer	6.75e-05	0.000575	CcSEcCtD
Telmisartan—Muscle spasms—Epirubicin—urinary bladder cancer	6.74e-05	0.000574	CcSEcCtD
Telmisartan—Immune system disorder—Doxorubicin—urinary bladder cancer	6.73e-05	0.000573	CcSEcCtD
Telmisartan—Vertigo—Methotrexate—urinary bladder cancer	6.73e-05	0.000573	CcSEcCtD
Telmisartan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	6.72e-05	0.000572	CcSEcCtD
Telmisartan—Chills—Doxorubicin—urinary bladder cancer	6.69e-05	0.000569	CcSEcCtD
Telmisartan—Arrhythmia—Doxorubicin—urinary bladder cancer	6.66e-05	0.000567	CcSEcCtD
Telmisartan—Nausea—Cisplatin—urinary bladder cancer	6.62e-05	0.000563	CcSEcCtD
Telmisartan—Cough—Methotrexate—urinary bladder cancer	6.54e-05	0.000557	CcSEcCtD
Telmisartan—Mental disorder—Doxorubicin—urinary bladder cancer	6.53e-05	0.000556	CcSEcCtD
Telmisartan—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.51e-05	0.000554	CcSEcCtD
Telmisartan—Vomiting—Etoposide—urinary bladder cancer	6.49e-05	0.000553	CcSEcCtD
Telmisartan—Erythema—Doxorubicin—urinary bladder cancer	6.49e-05	0.000552	CcSEcCtD
Telmisartan—Malnutrition—Doxorubicin—urinary bladder cancer	6.49e-05	0.000552	CcSEcCtD
Telmisartan—Anaemia—Epirubicin—urinary bladder cancer	6.48e-05	0.000552	CcSEcCtD
Telmisartan—Rash—Etoposide—urinary bladder cancer	6.44e-05	0.000548	CcSEcCtD
Telmisartan—Dermatitis—Etoposide—urinary bladder cancer	6.43e-05	0.000547	CcSEcCtD
Telmisartan—Headache—Etoposide—urinary bladder cancer	6.4e-05	0.000544	CcSEcCtD
Telmisartan—Flatulence—Doxorubicin—urinary bladder cancer	6.4e-05	0.000544	CcSEcCtD
Telmisartan—Myalgia—Methotrexate—urinary bladder cancer	6.38e-05	0.000543	CcSEcCtD
Telmisartan—Arthralgia—Methotrexate—urinary bladder cancer	6.38e-05	0.000543	CcSEcCtD
Telmisartan—Chest pain—Methotrexate—urinary bladder cancer	6.38e-05	0.000543	CcSEcCtD
Telmisartan—Tension—Doxorubicin—urinary bladder cancer	6.37e-05	0.000542	CcSEcCtD
Telmisartan—Dysgeusia—Doxorubicin—urinary bladder cancer	6.36e-05	0.000541	CcSEcCtD
Telmisartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.34e-05	0.000539	CcSEcCtD
Telmisartan—Malaise—Epirubicin—urinary bladder cancer	6.33e-05	0.000538	CcSEcCtD
Telmisartan—Discomfort—Methotrexate—urinary bladder cancer	6.31e-05	0.000536	CcSEcCtD
Telmisartan—Nervousness—Doxorubicin—urinary bladder cancer	6.3e-05	0.000536	CcSEcCtD
Telmisartan—Vertigo—Epirubicin—urinary bladder cancer	6.3e-05	0.000536	CcSEcCtD
Telmisartan—Syncope—Epirubicin—urinary bladder cancer	6.29e-05	0.000535	CcSEcCtD
Telmisartan—Back pain—Doxorubicin—urinary bladder cancer	6.28e-05	0.000534	CcSEcCtD
Telmisartan—Muscle spasms—Doxorubicin—urinary bladder cancer	6.24e-05	0.000531	CcSEcCtD
Telmisartan—Palpitations—Epirubicin—urinary bladder cancer	6.2e-05	0.000527	CcSEcCtD
Telmisartan—Loss of consciousness—Epirubicin—urinary bladder cancer	6.17e-05	0.000525	CcSEcCtD
Telmisartan—Cough—Epirubicin—urinary bladder cancer	6.12e-05	0.000521	CcSEcCtD
Telmisartan—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.12e-05	0.000521	CcSEcCtD
Telmisartan—Infection—Methotrexate—urinary bladder cancer	6.08e-05	0.000517	CcSEcCtD
Telmisartan—Nausea—Etoposide—urinary bladder cancer	6.07e-05	0.000516	CcSEcCtD
Telmisartan—Hypertension—Epirubicin—urinary bladder cancer	6.06e-05	0.000515	CcSEcCtD
Telmisartan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	6.02e-05	0.000512	CcSEcCtD
Telmisartan—Nervous system disorder—Methotrexate—urinary bladder cancer	6e-05	0.00051	CcSEcCtD
Telmisartan—Anaemia—Doxorubicin—urinary bladder cancer	6e-05	0.00051	CcSEcCtD
Telmisartan—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.99e-05	0.00051	CcSEcCtD
Telmisartan—Arthralgia—Epirubicin—urinary bladder cancer	5.97e-05	0.000508	CcSEcCtD
Telmisartan—Myalgia—Epirubicin—urinary bladder cancer	5.97e-05	0.000508	CcSEcCtD
Telmisartan—Chest pain—Epirubicin—urinary bladder cancer	5.97e-05	0.000508	CcSEcCtD
Telmisartan—Anxiety—Epirubicin—urinary bladder cancer	5.95e-05	0.000506	CcSEcCtD
Telmisartan—Skin disorder—Methotrexate—urinary bladder cancer	5.94e-05	0.000506	CcSEcCtD
Telmisartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	5.93e-05	0.000505	CcSEcCtD
Telmisartan—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.91e-05	0.000503	CcSEcCtD
Telmisartan—Discomfort—Epirubicin—urinary bladder cancer	5.9e-05	0.000502	CcSEcCtD
Telmisartan—Malaise—Doxorubicin—urinary bladder cancer	5.85e-05	0.000498	CcSEcCtD
Telmisartan—Dry mouth—Epirubicin—urinary bladder cancer	5.84e-05	0.000497	CcSEcCtD
Telmisartan—Vertigo—Doxorubicin—urinary bladder cancer	5.83e-05	0.000496	CcSEcCtD
Telmisartan—Anorexia—Methotrexate—urinary bladder cancer	5.83e-05	0.000496	CcSEcCtD
Telmisartan—Syncope—Doxorubicin—urinary bladder cancer	5.82e-05	0.000495	CcSEcCtD
Telmisartan—Palpitations—Doxorubicin—urinary bladder cancer	5.74e-05	0.000488	CcSEcCtD
Telmisartan—Oedema—Epirubicin—urinary bladder cancer	5.73e-05	0.000487	CcSEcCtD
Telmisartan—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.73e-05	0.000487	CcSEcCtD
Telmisartan—Hypotension—Methotrexate—urinary bladder cancer	5.72e-05	0.000486	CcSEcCtD
Telmisartan—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.7e-05	0.000485	CcSEcCtD
Telmisartan—Infection—Epirubicin—urinary bladder cancer	5.69e-05	0.000484	CcSEcCtD
Telmisartan—Cough—Doxorubicin—urinary bladder cancer	5.66e-05	0.000482	CcSEcCtD
Telmisartan—Shock—Epirubicin—urinary bladder cancer	5.63e-05	0.000479	CcSEcCtD
Telmisartan—Nervous system disorder—Epirubicin—urinary bladder cancer	5.61e-05	0.000478	CcSEcCtD
Telmisartan—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.61e-05	0.000477	CcSEcCtD
Telmisartan—Hypertension—Doxorubicin—urinary bladder cancer	5.6e-05	0.000477	CcSEcCtD
Telmisartan—Tachycardia—Epirubicin—urinary bladder cancer	5.59e-05	0.000475	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.57e-05	0.000474	CcSEcCtD
Telmisartan—Skin disorder—Epirubicin—urinary bladder cancer	5.56e-05	0.000473	CcSEcCtD
Telmisartan—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.53e-05	0.000471	CcSEcCtD
Telmisartan—Insomnia—Methotrexate—urinary bladder cancer	5.53e-05	0.000471	CcSEcCtD
Telmisartan—Arthralgia—Doxorubicin—urinary bladder cancer	5.53e-05	0.00047	CcSEcCtD
Telmisartan—Chest pain—Doxorubicin—urinary bladder cancer	5.53e-05	0.00047	CcSEcCtD
Telmisartan—Myalgia—Doxorubicin—urinary bladder cancer	5.53e-05	0.00047	CcSEcCtD
Telmisartan—Anxiety—Doxorubicin—urinary bladder cancer	5.51e-05	0.000469	CcSEcCtD
Telmisartan—Paraesthesia—Methotrexate—urinary bladder cancer	5.49e-05	0.000467	CcSEcCtD
Telmisartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	5.49e-05	0.000467	CcSEcCtD
Telmisartan—Discomfort—Doxorubicin—urinary bladder cancer	5.46e-05	0.000465	CcSEcCtD
Telmisartan—Anorexia—Epirubicin—urinary bladder cancer	5.46e-05	0.000464	CcSEcCtD
Telmisartan—Dyspnoea—Methotrexate—urinary bladder cancer	5.45e-05	0.000464	CcSEcCtD
Telmisartan—Somnolence—Methotrexate—urinary bladder cancer	5.44e-05	0.000463	CcSEcCtD
Telmisartan—Dry mouth—Doxorubicin—urinary bladder cancer	5.4e-05	0.00046	CcSEcCtD
Telmisartan—Dyspepsia—Methotrexate—urinary bladder cancer	5.39e-05	0.000458	CcSEcCtD
Telmisartan—Hypotension—Epirubicin—urinary bladder cancer	5.35e-05	0.000455	CcSEcCtD
Telmisartan—Decreased appetite—Methotrexate—urinary bladder cancer	5.32e-05	0.000452	CcSEcCtD
Telmisartan—Oedema—Doxorubicin—urinary bladder cancer	5.3e-05	0.000451	CcSEcCtD
Telmisartan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.3e-05	0.000451	CcSEcCtD
Telmisartan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.28e-05	0.000449	CcSEcCtD
Telmisartan—Fatigue—Methotrexate—urinary bladder cancer	5.27e-05	0.000449	CcSEcCtD
Telmisartan—Infection—Doxorubicin—urinary bladder cancer	5.26e-05	0.000448	CcSEcCtD
Telmisartan—Pain—Methotrexate—urinary bladder cancer	5.23e-05	0.000445	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.22e-05	0.000444	CcSEcCtD
Telmisartan—Shock—Doxorubicin—urinary bladder cancer	5.21e-05	0.000443	CcSEcCtD
Telmisartan—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.19e-05	0.000442	CcSEcCtD
Telmisartan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.19e-05	0.000441	CcSEcCtD
Telmisartan—Insomnia—Epirubicin—urinary bladder cancer	5.18e-05	0.000441	CcSEcCtD
Telmisartan—Tachycardia—Doxorubicin—urinary bladder cancer	5.17e-05	0.00044	CcSEcCtD
Telmisartan—Skin disorder—Doxorubicin—urinary bladder cancer	5.15e-05	0.000438	CcSEcCtD
Telmisartan—Paraesthesia—Epirubicin—urinary bladder cancer	5.14e-05	0.000437	CcSEcCtD
Telmisartan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.12e-05	0.000436	CcSEcCtD
Telmisartan—Dyspnoea—Epirubicin—urinary bladder cancer	5.1e-05	0.000434	CcSEcCtD
Telmisartan—Somnolence—Epirubicin—urinary bladder cancer	5.09e-05	0.000433	CcSEcCtD
Telmisartan—Anorexia—Doxorubicin—urinary bladder cancer	5.05e-05	0.00043	CcSEcCtD
Telmisartan—Feeling abnormal—Methotrexate—urinary bladder cancer	5.04e-05	0.000429	CcSEcCtD
Telmisartan—Dyspepsia—Epirubicin—urinary bladder cancer	5.04e-05	0.000429	CcSEcCtD
Telmisartan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5e-05	0.000426	CcSEcCtD
Telmisartan—SLCO1B3—Metabolism—PRSS3—urinary bladder cancer	4.99e-05	0.00152	CbGpPWpGaD
Telmisartan—Decreased appetite—Epirubicin—urinary bladder cancer	4.98e-05	0.000423	CcSEcCtD
Telmisartan—Hypotension—Doxorubicin—urinary bladder cancer	4.95e-05	0.000421	CcSEcCtD
Telmisartan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.94e-05	0.000421	CcSEcCtD
Telmisartan—Fatigue—Epirubicin—urinary bladder cancer	4.94e-05	0.00042	CcSEcCtD
Telmisartan—Constipation—Epirubicin—urinary bladder cancer	4.9e-05	0.000417	CcSEcCtD
Telmisartan—Pain—Epirubicin—urinary bladder cancer	4.9e-05	0.000417	CcSEcCtD
Telmisartan—Urticaria—Methotrexate—urinary bladder cancer	4.86e-05	0.000414	CcSEcCtD
Telmisartan—Abdominal pain—Methotrexate—urinary bladder cancer	4.84e-05	0.000411	CcSEcCtD
Telmisartan—Body temperature increased—Methotrexate—urinary bladder cancer	4.84e-05	0.000411	CcSEcCtD
Telmisartan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.83e-05	0.000411	CcSEcCtD
Telmisartan—Insomnia—Doxorubicin—urinary bladder cancer	4.79e-05	0.000408	CcSEcCtD
Telmisartan—Paraesthesia—Doxorubicin—urinary bladder cancer	4.76e-05	0.000405	CcSEcCtD
Telmisartan—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	4.72e-05	0.00144	CbGpPWpGaD
Telmisartan—Dyspnoea—Doxorubicin—urinary bladder cancer	4.72e-05	0.000402	CcSEcCtD
Telmisartan—Feeling abnormal—Epirubicin—urinary bladder cancer	4.72e-05	0.000401	CcSEcCtD
Telmisartan—Somnolence—Doxorubicin—urinary bladder cancer	4.71e-05	0.000401	CcSEcCtD
Telmisartan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.68e-05	0.000398	CcSEcCtD
Telmisartan—Dyspepsia—Doxorubicin—urinary bladder cancer	4.66e-05	0.000397	CcSEcCtD
Telmisartan—PPARG—Metabolism—CYP4B1—urinary bladder cancer	4.62e-05	0.00141	CbGpPWpGaD
Telmisartan—Decreased appetite—Doxorubicin—urinary bladder cancer	4.6e-05	0.000392	CcSEcCtD
Telmisartan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.57e-05	0.000389	CcSEcCtD
Telmisartan—Fatigue—Doxorubicin—urinary bladder cancer	4.57e-05	0.000389	CcSEcCtD
Telmisartan—AGTR1—Signaling Pathways—HDAC4—urinary bladder cancer	4.56e-05	0.00139	CbGpPWpGaD
Telmisartan—Urticaria—Epirubicin—urinary bladder cancer	4.55e-05	0.000387	CcSEcCtD
Telmisartan—Constipation—Doxorubicin—urinary bladder cancer	4.53e-05	0.000385	CcSEcCtD
Telmisartan—Pain—Doxorubicin—urinary bladder cancer	4.53e-05	0.000385	CcSEcCtD
Telmisartan—Abdominal pain—Epirubicin—urinary bladder cancer	4.53e-05	0.000385	CcSEcCtD
Telmisartan—Body temperature increased—Epirubicin—urinary bladder cancer	4.53e-05	0.000385	CcSEcCtD
Telmisartan—Hypersensitivity—Methotrexate—urinary bladder cancer	4.51e-05	0.000383	CcSEcCtD
Telmisartan—Asthenia—Methotrexate—urinary bladder cancer	4.39e-05	0.000373	CcSEcCtD
Telmisartan—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.37e-05	0.000371	CcSEcCtD
Telmisartan—PPARG—Metabolism—SLC19A1—urinary bladder cancer	4.36e-05	0.00133	CbGpPWpGaD
Telmisartan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.33e-05	0.000369	CcSEcCtD
Telmisartan—Pruritus—Methotrexate—urinary bladder cancer	4.33e-05	0.000368	CcSEcCtD
Telmisartan—ABCG2—Metabolism—GSTZ1—urinary bladder cancer	4.32e-05	0.00131	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—PRSS3—urinary bladder cancer	4.25e-05	0.0013	CbGpPWpGaD
Telmisartan—PPARG—Adipogenesis—TNF—urinary bladder cancer	4.23e-05	0.00129	CbGpPWpGaD
Telmisartan—Hypersensitivity—Epirubicin—urinary bladder cancer	4.22e-05	0.000359	CcSEcCtD
Telmisartan—Urticaria—Doxorubicin—urinary bladder cancer	4.21e-05	0.000358	CcSEcCtD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.19e-05	0.00128	CbGpPWpGaD
Telmisartan—Abdominal pain—Doxorubicin—urinary bladder cancer	4.19e-05	0.000356	CcSEcCtD
Telmisartan—Body temperature increased—Doxorubicin—urinary bladder cancer	4.19e-05	0.000356	CcSEcCtD
Telmisartan—Diarrhoea—Methotrexate—urinary bladder cancer	4.19e-05	0.000356	CcSEcCtD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	4.17e-05	0.00127	CbGpPWpGaD
Telmisartan—Asthenia—Epirubicin—urinary bladder cancer	4.11e-05	0.000349	CcSEcCtD
Telmisartan—ABCG2—Metabolism—GSTO2—urinary bladder cancer	4.09e-05	0.00125	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—NAT1—urinary bladder cancer	4.09e-05	0.00125	CbGpPWpGaD
Telmisartan—PPARG—Generic Transcription Pathway—NCOR1—urinary bladder cancer	4.06e-05	0.00124	CbGpPWpGaD
Telmisartan—Pruritus—Epirubicin—urinary bladder cancer	4.05e-05	0.000345	CcSEcCtD
Telmisartan—Dizziness—Methotrexate—urinary bladder cancer	4.05e-05	0.000344	CcSEcCtD
Telmisartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.04e-05	0.00123	CbGpPWpGaD
Telmisartan—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	4.02e-05	0.00122	CbGpPWpGaD
Telmisartan—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4e-05	0.00122	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4e-05	0.00122	CbGpPWpGaD
Telmisartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	3.99e-05	0.00121	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—TYMP—urinary bladder cancer	3.99e-05	0.00121	CbGpPWpGaD
Telmisartan—Diarrhoea—Epirubicin—urinary bladder cancer	3.92e-05	0.000333	CcSEcCtD
Telmisartan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	3.91e-05	0.00119	CbGpPWpGaD
Telmisartan—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	3.9e-05	0.00119	CbGpPWpGaD
Telmisartan—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.9e-05	0.000332	CcSEcCtD
Telmisartan—Vomiting—Methotrexate—urinary bladder cancer	3.89e-05	0.000331	CcSEcCtD
Telmisartan—Rash—Methotrexate—urinary bladder cancer	3.86e-05	0.000328	CcSEcCtD
Telmisartan—PPARG—Circadian rythm related genes—PTEN—urinary bladder cancer	3.85e-05	0.00117	CbGpPWpGaD
Telmisartan—Dermatitis—Methotrexate—urinary bladder cancer	3.85e-05	0.000328	CcSEcCtD
Telmisartan—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.85e-05	0.00117	CbGpPWpGaD
Telmisartan—Headache—Methotrexate—urinary bladder cancer	3.83e-05	0.000326	CcSEcCtD
Telmisartan—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.83e-05	0.00117	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—GLI1—urinary bladder cancer	3.82e-05	0.00116	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—NCOR1—urinary bladder cancer	3.82e-05	0.00116	CbGpPWpGaD
Telmisartan—Asthenia—Doxorubicin—urinary bladder cancer	3.8e-05	0.000323	CcSEcCtD
Telmisartan—Dizziness—Epirubicin—urinary bladder cancer	3.79e-05	0.000322	CcSEcCtD
Telmisartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	3.77e-05	0.00115	CbGpPWpGaD
Telmisartan—Pruritus—Doxorubicin—urinary bladder cancer	3.75e-05	0.000319	CcSEcCtD
Telmisartan—ABCG2—Metabolism—UGT2B7—urinary bladder cancer	3.74e-05	0.00114	CbGpPWpGaD
Telmisartan—PPARG—Circadian rythm related genes—EP300—urinary bladder cancer	3.68e-05	0.00112	CbGpPWpGaD
Telmisartan—Vomiting—Epirubicin—urinary bladder cancer	3.64e-05	0.00031	CcSEcCtD
Telmisartan—Nausea—Methotrexate—urinary bladder cancer	3.63e-05	0.000309	CcSEcCtD
Telmisartan—Diarrhoea—Doxorubicin—urinary bladder cancer	3.62e-05	0.000308	CcSEcCtD
Telmisartan—Rash—Epirubicin—urinary bladder cancer	3.61e-05	0.000307	CcSEcCtD
Telmisartan—Dermatitis—Epirubicin—urinary bladder cancer	3.61e-05	0.000307	CcSEcCtD
Telmisartan—SLCO1B3—Metabolism—NAT2—urinary bladder cancer	3.6e-05	0.0011	CbGpPWpGaD
Telmisartan—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	3.59e-05	0.00109	CbGpPWpGaD
Telmisartan—Headache—Epirubicin—urinary bladder cancer	3.59e-05	0.000305	CcSEcCtD
Telmisartan—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	3.57e-05	0.00109	CbGpPWpGaD
Telmisartan—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.54e-05	0.00108	CbGpPWpGaD
Telmisartan—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.53e-05	0.00108	CbGpPWpGaD
Telmisartan—Dizziness—Doxorubicin—urinary bladder cancer	3.5e-05	0.000298	CcSEcCtD
Telmisartan—ABCG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.48e-05	0.00106	CbGpPWpGaD
Telmisartan—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.42e-05	0.00104	CbGpPWpGaD
Telmisartan—PPARG—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.41e-05	0.00104	CbGpPWpGaD
Telmisartan—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	3.41e-05	0.00104	CbGpPWpGaD
Telmisartan—Nausea—Epirubicin—urinary bladder cancer	3.4e-05	0.000289	CcSEcCtD
Telmisartan—PPARG—Metabolism—TYMP—urinary bladder cancer	3.4e-05	0.00104	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—CYP4B1—urinary bladder cancer	3.37e-05	0.00103	CbGpPWpGaD
Telmisartan—Vomiting—Doxorubicin—urinary bladder cancer	3.37e-05	0.000287	CcSEcCtD
Telmisartan—Rash—Doxorubicin—urinary bladder cancer	3.34e-05	0.000284	CcSEcCtD
Telmisartan—Dermatitis—Doxorubicin—urinary bladder cancer	3.34e-05	0.000284	CcSEcCtD
Telmisartan—Headache—Doxorubicin—urinary bladder cancer	3.32e-05	0.000282	CcSEcCtD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.32e-05	0.00101	CbGpPWpGaD
Telmisartan—PPARG—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.27e-05	0.000995	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.26e-05	0.000992	CbGpPWpGaD
Telmisartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	3.2e-05	0.000975	CbGpPWpGaD
Telmisartan—PPARG—Generic Transcription Pathway—ESR1—urinary bladder cancer	3.19e-05	0.000971	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—SLC19A1—urinary bladder cancer	3.18e-05	0.000969	CbGpPWpGaD
Telmisartan—Nausea—Doxorubicin—urinary bladder cancer	3.15e-05	0.000268	CcSEcCtD
Telmisartan—SLCO1B3—Metabolism—RRM2—urinary bladder cancer	3.11e-05	0.000948	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—PRSS3—urinary bladder cancer	3.1e-05	0.000945	CbGpPWpGaD
Telmisartan—AGTR1—GPCR ligand binding—CXCL8—urinary bladder cancer	3.08e-05	0.000937	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—NAT2—urinary bladder cancer	3.08e-05	0.000937	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—CDK4—urinary bladder cancer	3.01e-05	0.000917	CbGpPWpGaD
Telmisartan—PPARG—Gene Expression—SMC1A—urinary bladder cancer	2.9e-05	0.000884	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.89e-05	0.000879	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—HPGDS—urinary bladder cancer	2.88e-05	0.000878	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—ENO2—urinary bladder cancer	2.88e-05	0.000878	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.86e-05	0.000872	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—GSTT1—urinary bladder cancer	2.79e-05	0.000851	CbGpPWpGaD
Telmisartan—PPARG—Generic Transcription Pathway—CREBBP—urinary bladder cancer	2.79e-05	0.000851	CbGpPWpGaD
Telmisartan—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.78e-05	0.000848	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.75e-05	0.000838	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—RRM2—urinary bladder cancer	2.65e-05	0.000808	CbGpPWpGaD
Telmisartan—PPARG—Circadian rythm related genes—TP53—urinary bladder cancer	2.63e-05	0.000801	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—CREBBP—urinary bladder cancer	2.63e-05	0.000801	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—RBX1—urinary bladder cancer	2.62e-05	0.000797	CbGpPWpGaD
Telmisartan—SLCO1B3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.62e-05	0.000797	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.55e-05	0.000777	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.54e-05	0.000773	CbGpPWpGaD
Telmisartan—PPARG—Gene Expression—ESR2—urinary bladder cancer	2.53e-05	0.00077	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.53e-05	0.00077	CbGpPWpGaD
Telmisartan—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.48e-05	0.000756	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—TYMP—urinary bladder cancer	2.48e-05	0.000755	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—TSC1—urinary bladder cancer	2.46e-05	0.00075	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—ENO2—urinary bladder cancer	2.46e-05	0.000749	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—HPGDS—urinary bladder cancer	2.46e-05	0.000749	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	2.39e-05	0.000728	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—GSTT1—urinary bladder cancer	2.38e-05	0.000726	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—RHOA—urinary bladder cancer	2.38e-05	0.000724	CbGpPWpGaD
Telmisartan—PPARG—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.35e-05	0.000715	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—JAG1—urinary bladder cancer	2.34e-05	0.000714	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.33e-05	0.000711	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—NQO1—urinary bladder cancer	2.32e-05	0.000707	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	2.27e-05	0.00069	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—NAT1—urinary bladder cancer	2.27e-05	0.00069	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.25e-05	0.000686	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—NAT2—urinary bladder cancer	2.24e-05	0.000683	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.23e-05	0.000679	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.22e-05	0.000675	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.21e-05	0.000674	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.21e-05	0.000674	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—ERBB2—urinary bladder cancer	2.2e-05	0.000671	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.19e-05	0.000667	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	2.07e-05	0.000631	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.02e-05	0.000616	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—NQO1—urinary bladder cancer	1.98e-05	0.000604	CbGpPWpGaD
Telmisartan—AGTR1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.98e-05	0.000603	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.97e-05	0.000599	CbGpPWpGaD
Telmisartan—PPARG—Gene Expression—NCOR1—urinary bladder cancer	1.95e-05	0.000595	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—GSTP1—urinary bladder cancer	1.94e-05	0.00059	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—RRM2—urinary bladder cancer	1.94e-05	0.000589	CbGpPWpGaD
Telmisartan—PPARG—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.92e-05	0.000586	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—S100B—urinary bladder cancer	1.9e-05	0.000578	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—MMP9—urinary bladder cancer	1.89e-05	0.000575	CbGpPWpGaD
Telmisartan—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.88e-05	0.000573	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.87e-05	0.000571	CbGpPWpGaD
Telmisartan—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.87e-05	0.00057	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	1.87e-05	0.000569	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.86e-05	0.000565	CbGpPWpGaD
Telmisartan—PPARG—Gene Expression—ERCC2—urinary bladder cancer	1.84e-05	0.000559	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.82e-05	0.000555	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.82e-05	0.000553	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—TYMS—urinary bladder cancer	1.8e-05	0.000548	CbGpPWpGaD
Telmisartan—AGTR1—Signaling by GPCR—RHOA—urinary bladder cancer	1.8e-05	0.000548	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—ENO2—urinary bladder cancer	1.79e-05	0.000546	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—HPGDS—urinary bladder cancer	1.79e-05	0.000546	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—EP300—urinary bladder cancer	1.79e-05	0.000545	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—NCOR1—urinary bladder cancer	1.78e-05	0.000542	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—GSTM1—urinary bladder cancer	1.78e-05	0.000542	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	1.76e-05	0.000537	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—SRC—urinary bladder cancer	1.74e-05	0.00053	CbGpPWpGaD
Telmisartan—AGTR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.74e-05	0.00053	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—GSTT1—urinary bladder cancer	1.74e-05	0.000529	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.72e-05	0.000524	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	1.72e-05	0.000523	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.71e-05	0.00052	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—GPX1—urinary bladder cancer	1.7e-05	0.000519	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.68e-05	0.000511	CbGpPWpGaD
Telmisartan—PPARG—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.68e-05	0.000511	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	1.67e-05	0.00051	CbGpPWpGaD
Telmisartan—AGTR1—GPCR downstream signaling—IL2—urinary bladder cancer	1.66e-05	0.000506	CbGpPWpGaD
Telmisartan—PPARG—Generic Transcription Pathway—MYC—urinary bladder cancer	1.66e-05	0.000505	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—GSTP1—urinary bladder cancer	1.65e-05	0.000503	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.64e-05	0.000499	CbGpPWpGaD
Telmisartan—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.63e-05	0.000496	CbGpPWpGaD
Telmisartan—PPARG—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.6e-05	0.000487	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.59e-05	0.000483	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.58e-05	0.000482	CbGpPWpGaD
Telmisartan—AGTR1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.58e-05	0.000481	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	1.57e-05	0.000479	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—TYMS—urinary bladder cancer	1.54e-05	0.000468	CbGpPWpGaD
Telmisartan—PPARG—Gene Expression—ESR1—urinary bladder cancer	1.53e-05	0.000467	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—EGFR—urinary bladder cancer	1.53e-05	0.000465	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—NCOR1—urinary bladder cancer	1.52e-05	0.000463	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—GSTM1—urinary bladder cancer	1.52e-05	0.000463	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.51e-05	0.00046	CbGpPWpGaD
Telmisartan—AGTR1—Signaling by GPCR—IL2—urinary bladder cancer	1.51e-05	0.00046	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—TERT—urinary bladder cancer	1.5e-05	0.000458	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.47e-05	0.000447	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—GPX1—urinary bladder cancer	1.45e-05	0.000443	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—TNF—urinary bladder cancer	1.45e-05	0.000443	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—NQO1—urinary bladder cancer	1.44e-05	0.00044	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—KRAS—urinary bladder cancer	1.44e-05	0.000439	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—ERCC2—urinary bladder cancer	1.43e-05	0.000435	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—FGFR3—urinary bladder cancer	1.38e-05	0.00042	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.38e-05	0.000419	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.37e-05	0.000418	CbGpPWpGaD
Telmisartan—PPARG—Gene Expression—CREBBP—urinary bladder cancer	1.34e-05	0.00041	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—MTHFR—urinary bladder cancer	1.34e-05	0.000409	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.34e-05	0.000408	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—ESR1—urinary bladder cancer	1.34e-05	0.000408	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.32e-05	0.000402	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.32e-05	0.000401	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.29e-05	0.000392	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	1.28e-05	0.000389	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.24e-05	0.000378	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	1.23e-05	0.000373	CbGpPWpGaD
Telmisartan—PPARG—Developmental Biology—HRAS—urinary bladder cancer	1.23e-05	0.000373	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.23e-05	0.000373	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.22e-05	0.00037	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.21e-05	0.000369	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—GSTP1—urinary bladder cancer	1.21e-05	0.000367	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—CREBBP—urinary bladder cancer	1.17e-05	0.000358	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—IGF1—urinary bladder cancer	1.16e-05	0.000353	CbGpPWpGaD
Telmisartan—AGTR1—Signaling by GPCR—EGFR—urinary bladder cancer	1.15e-05	0.000351	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—TYMS—urinary bladder cancer	1.12e-05	0.000341	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—GSTM1—urinary bladder cancer	1.11e-05	0.000337	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—NCOR1—urinary bladder cancer	1.11e-05	0.000337	CbGpPWpGaD
Telmisartan—AGTR1—Signaling by GPCR—KRAS—urinary bladder cancer	1.09e-05	0.000332	CbGpPWpGaD
Telmisartan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.08e-05	0.000329	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.07e-05	0.000327	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—RHOA—urinary bladder cancer	1.06e-05	0.000324	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—GPX1—urinary bladder cancer	1.06e-05	0.000323	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.05e-05	0.000319	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—CREBBP—urinary bladder cancer	1.05e-05	0.000318	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—ERCC2—urinary bladder cancer	1.04e-05	0.000317	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	1e-05	0.000306	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—ENO2—urinary bladder cancer	9.93e-06	0.000302	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	9.93e-06	0.000302	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.87e-06	0.000301	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—ERBB2—urinary bladder cancer	9.84e-06	0.0003	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—MTHFR—urinary bladder cancer	9.79e-06	0.000298	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—HPGDS—urinary bladder cancer	9.69e-06	0.000295	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—ENO2—urinary bladder cancer	9.69e-06	0.000295	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	9.63e-06	0.000293	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.48e-06	0.000289	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—GSTT1—urinary bladder cancer	9.4e-06	0.000286	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—CXCL8—urinary bladder cancer	9.33e-06	0.000284	CbGpPWpGaD
Telmisartan—AGTR1—Signaling by GPCR—HRAS—urinary bladder cancer	9.27e-06	0.000282	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—IL2—urinary bladder cancer	8.91e-06	0.000271	CbGpPWpGaD
Telmisartan—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.8e-06	0.000268	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	8.75e-06	0.000267	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—CCND1—urinary bladder cancer	8.69e-06	0.000265	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—PTGS2—urinary bladder cancer	8.56e-06	0.000261	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—MMP9—urinary bladder cancer	8.44e-06	0.000257	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.41e-06	0.000256	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—PTEN—urinary bladder cancer	8.39e-06	0.000255	CbGpPWpGaD
Telmisartan—SLCO1B3—Metabolism—EP300—urinary bladder cancer	8.35e-06	0.000254	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—NQO1—urinary bladder cancer	8e-06	0.000244	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—EP300—urinary bladder cancer	8e-06	0.000244	CbGpPWpGaD
Telmisartan—PPARG—Gene Expression—MYC—urinary bladder cancer	7.98e-06	0.000243	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—PPARG—urinary bladder cancer	7.94e-06	0.000242	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—NQO1—urinary bladder cancer	7.81e-06	0.000238	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—SRC—urinary bladder cancer	7.78e-06	0.000237	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.77e-06	0.000236	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—CREBBP—urinary bladder cancer	7.62e-06	0.000232	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—PTEN—urinary bladder cancer	7.47e-06	0.000227	CbGpPWpGaD
Telmisartan—PPARG—Metabolism—EP300—urinary bladder cancer	7.12e-06	0.000217	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—MYC—urinary bladder cancer	6.97e-06	0.000212	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—EGFR—urinary bladder cancer	6.82e-06	0.000208	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.77e-06	0.000206	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	6.68e-06	0.000203	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—GSTP1—urinary bladder cancer	6.52e-06	0.000198	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.46e-06	0.000197	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—KRAS—urinary bladder cancer	6.44e-06	0.000196	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—PTGS2—urinary bladder cancer	6.24e-06	0.00019	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—TYMS—urinary bladder cancer	6.21e-06	0.000189	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	6.13e-06	0.000187	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	6.13e-06	0.000187	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—TYMS—urinary bladder cancer	6.06e-06	0.000184	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.99e-06	0.000182	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.99e-06	0.000182	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—GPX1—urinary bladder cancer	5.87e-06	0.000179	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	5.77e-06	0.000176	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.73e-06	0.000175	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—TP53—urinary bladder cancer	5.72e-06	0.000174	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—ERCC2—urinary bladder cancer	5.63e-06	0.000171	CbGpPWpGaD
Telmisartan—AGTR1—Signaling Pathways—HRAS—urinary bladder cancer	5.47e-06	0.000167	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—PTEN—urinary bladder cancer	5.44e-06	0.000166	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	5.42e-06	0.000165	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.29e-06	0.000161	CbGpPWpGaD
Telmisartan—ABCG2—Metabolism—EP300—urinary bladder cancer	5.19e-06	0.000158	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—PPARG—urinary bladder cancer	4.4e-06	0.000134	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.29e-06	0.000131	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	4.22e-06	0.000129	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.12e-06	0.000126	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	3.46e-06	0.000105	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.38e-06	0.000103	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—PTEN—urinary bladder cancer	3.02e-06	9.19e-05	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.94e-06	8.97e-05	CbGpPWpGaD
Telmisartan—CYP2C19—Metabolism—EP300—urinary bladder cancer	2.88e-06	8.76e-05	CbGpPWpGaD
Telmisartan—ABCB1—Metabolism—EP300—urinary bladder cancer	2.81e-06	8.55e-05	CbGpPWpGaD
